Close Menu

NEW YORK — Smiths Detection said on Wednesday that it has partnered with Attomarker on the development and manufacture of a SARS-CoV-2 antibody testing device.

UK-based Attomarker was spun out of the University of Exeter to develop a handheld device that works with a smartphone to rapidly measure blood biomarkers for liver disease and food allergens, as well as C-reactive protein. The company has also developed a test designed to detect immunoglobulin M, G, and A antibodies against SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.